TransMedics Group is spending this year's operating profit to buy the next decade of organ-transplant growth, and the second-quarter print makes that trade explicit. Revenue kept compounding at a mid-twenties pace while income from operations fell as the company poured spending into OCS Kidney, the next-generation platform, and two large clinical programs. The equity debate is not whether the Organ Care System still takes share. It is whether the National OCS Program can keep converting unused donor organs into paid cases fast enough to justify a year of compressed margins.
Service revenue grew faster than product revenue, and that mix shift is the entire margin story. Product sales still carry a high-seventies gross margin, while logistics and perfusion services sit in the mid-thirties. Sequential service-margin recovery from the first quarter shows the owned aviation fleet is starting to earn its keep, with internal coverage of National OCS Program air missions now in the mid-eighties. Management raised only the low end of full-year revenue guidance and simultaneously cut the adjusted operating-margin outlook. That pairing tells investors the growth is real and the spending is not a one-quarter event.
The July close of the PAD Aviation stake and the Food and Drug Administration investigational-device clearances for the ENHANCE Heart and DENOVO Lung trials are the named events behind the spend. Full-year revenue guidance now runs from $737 million to $757 million. That range excludes PAD Aviation and assumes no trial revenue. Cash of $473 million at mid-year funds the program without a new equity raise. The open question is whether the next year of clinical evidence, Kidney progress, and European logistics converts this margin dip into a larger franchise, or whether the multiple stays compressed until earnings re-accelerate.